Measurable Residual Disease and Posttransplantation Gilteritinib Maintenance for Patients with FLT3-ITD-Mutated AML

BMT CTN 1506 was a randomized Phase III study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation for patients with FLT3-ITD-mutated AML.